A Double-Blind, Positive Comparator, Randomized, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients with Mild to Moderate Dementia of the Alzheimer's Type (AD).

Trial Profile

A Double-Blind, Positive Comparator, Randomized, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients with Mild to Moderate Dementia of the Alzheimer's Type (AD).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Ispronicline (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Targacept
  • Most Recent Events

    • 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Jul 2014 Primary endpoint 'change from Baseline to week 52 in ADAS-Cog-11 and the Clinician Interview- Based Impression of Change Plus Caregiver Input (CIBIC-(+))' has not been met according to the Targacept media release.
    • 14 Jul 2014 Primary endpoint 'Change from Baseline to Week 52 in the co-primary endpoints ADAS-Cog-11 and the ADCS-ADL' has not been met (for European regulatory purposes) according to the Targacept media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top